“This pandemic-driven frenzy for drugmaker stocks has made it awfully hard for investors who like to focus on the fundamentals,” notes the author of today’s article – and as a result he proceeds to highlight two biotech stocks which have upcoming catalysts that have nothing to do with COVID-19. While one of these stocks may be too risky for most at the moment, the other could be a buy right now. For more, CLICK HERE.